Postexposure prevention of HIV infection or seroconversion

Details Postexposure prevention of HIV infection or seroconversion Postexposure prevention of HIV infection or seroconversion

1994-05-31

1997-03-18

Kunz, Gary L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514885, 536 282, 536 285, A61K 3170

Patent

active

056123191

ABSTRACT:
A method of preventing the establishment of HIV infection and/or HIV seroconversion in a human or simian comprising the administration of an effective amount of the compound 1-[2',3'-dideoxy-3'C-(hydroxymethyl)-.beta.-D-erythropentofuranosyl]-cytos ine having the following formula: ##STR1## or a pharmaceutically acceptable salt thereof, after exposure of said human or simian to HIV.

REFERENCES:
patent: 5215970 (1993-06-01), Datema et al.
Beninger, Paul R. et al., Postexposure Chemoprophylaxis: Approval Criteria for Clinical Trials, Journ. of Acquired Immune Deficiency Syndromes, vol. 4, 1991, (pp. 513-515).
Lange, Joep M.A. et al., Failure of Zidovudine Prophylaxis After Accidental Exposure to HIV-1, New England Jour. Med., May 10, 1990, vol. 322, No. 19 (pp. 1375-1377).
van Rompay, Koen K. et al., Simian Immunodeficiency Virus (SIV) Infection of Infant Rhesus Macaques as a Model to Test Antiretroviral Drug Prophylaxis and Therapy: Oral 3'-Azido-3'-Deoxythymidine Prevents SIV Infection, Antimicrobial Agents and Chemotherapy, Nov. 1992, (pp. 2381-2386).
Fazely, Fatemeh et al., Postexposure Chemoprophylaxis with ZDV or ZDV Combined with Interferon-.alpha.: Failure After Inoculating Rhesus Monkeys with a High Dose of SIV, Journ. of Acquired Immune Deficiency Syndromes, 1991, vol. 4, No. 11 (pp. 1093-1097).
Niu, Manette T. et al., Primary Human Immunodeficiency Virus Type 1 Infection: Review of Pathogenesis and Early Treatment Intervention in Humans and Animal Retrovirus Infections, Jour. of Infectious Diseases, 1993, vol. 168, (pp. 1490-1501).
Lundgren, B. et al., Acute Infection of Cynomolgus Monkeys with Simian Immunodeficiency Virus (SIV.sub.SM) as a Model to Evaluate Antiviral Compounds. Effects of 3'-Azido,3'-Deoxythymidine, Foscarnet and 2',3'-Dideoxycytidine, Antiviral Chemistry & Chemotherapy, 1990, 1(5), (pp. 299-306).
B ottiger, D. et al., Treatment of Acute SIV Infection in Cynomolgus Monkeys with 2',3'-Dideoxyinosine (ddl) and 2',3'-Dideoxythymidiene (d4T), Antiviral Chemistry & Chemotherapy, 1991, 2(6), (pp. 357-361).
B ottiger, D. et al., Prevention of HIV-2 and SIV Infections in Cynomolgus Macaques by Prophylactic Treatment with 3'-Fluorothymidine, Aids Research and Human Retroviruses, vol. 8, No. 7, 1992 (pp. 1235-1238).
Lundgren, Bj orn et al., Antiviral Effects of 3'-Fluorothymidine and 3'-Azidothymidine in Cynomolgus Monkeys Infected with Simian Immunodeficiency Virus, Journ. of Acquired Immune Deficiency Syndromes, vol. 4, 1991, (pp. 489-498).

Affiliated with

Also associated with

Rating

Postexposure prevention of HIV infection or seroconversion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Postexposure prevention of HIV infection or seroconversion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Postexposure prevention of HIV infection or seroconversion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1706405